share_log

424B3: Prospectus

424B3: Prospectus

424B3：募資說明書
美股SEC公告 ·  05/29 17:14
Moomoo AI 已提取核心訊息
Apollomics Inc., a biopharmaceutical company, has announced a secondary offering of 19,166,666 Class A ordinary shares. The shares are being offered by selling securityholders pursuant to subscription agreements dated May 6, 2024. The offering is part of a registration rights agreement to satisfy registration rights granted by the company. The selling securityholders may sell the shares through public or private transactions at market prices or negotiated prices. The shares are listed on the Nasdaq Capital Market under the symbol 'APLM'. The company will not receive any proceeds from the sale of shares by the selling securityholders. Apollomics, incorporated in the Cayman Islands with operations in the U.S. and China, is considered an emerging growth company and a foreign private issuer, exempt from certain U.S. reporting requirements. The company has not paid dividends and does not anticipate doing so in the foreseeable future. The date of the prospectus is May 29, 2024.
Apollomics Inc., a biopharmaceutical company, has announced a secondary offering of 19,166,666 Class A ordinary shares. The shares are being offered by selling securityholders pursuant to subscription agreements dated May 6, 2024. The offering is part of a registration rights agreement to satisfy registration rights granted by the company. The selling securityholders may sell the shares through public or private transactions at market prices or negotiated prices. The shares are listed on the Nasdaq Capital Market under the symbol 'APLM'. The company will not receive any proceeds from the sale of shares by the selling securityholders. Apollomics, incorporated in the Cayman Islands with operations in the U.S. and China, is considered an emerging growth company and a foreign private issuer, exempt from certain U.S. reporting requirements. The company has not paid dividends and does not anticipate doing so in the foreseeable future. The date of the prospectus is May 29, 2024.
生物製藥公司Apollomics Inc. 宣佈二次發行19,1666股A類普通股。根據2024年5月6日的認購協議，這些股票由出售證券持有人發行。此次發行是註冊權協議的一部分，旨在滿足公司授予的註冊權。出售證券的持有人可以通過公開或私人交易以市場價格或協議價格出售股票。這些股票在納斯達克資本市場上市，股票代碼爲 “APLM”。該公司不會從出售證券持有人出售股票中獲得任何收益。Apollomics在開曼群島註冊成立，在美國和中國開展業務，被視爲新興成長型公司和外國私人發行人，不受某些美國報告要求的約束。該公司尚未支付股息，預計在可預見的將來也不會派發股息。招股說明書的發佈日期爲2024年5月29日。
生物製藥公司Apollomics Inc. 宣佈二次發行19,1666股A類普通股。根據2024年5月6日的認購協議，這些股票由出售證券持有人發行。此次發行是註冊權協議的一部分，旨在滿足公司授予的註冊權。出售證券的持有人可以通過公開或私人交易以市場價格或協議價格出售股票。這些股票在納斯達克資本市場上市，股票代碼爲 “APLM”。該公司不會從出售證券持有人出售股票中獲得任何收益。Apollomics在開曼群島註冊成立，在美國和中國開展業務，被視爲新興成長型公司和外國私人發行人，不受某些美國報告要求的約束。該公司尚未支付股息，預計在可預見的將來也不會派發股息。招股說明書的發佈日期爲2024年5月29日。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息